Global Mumps Drug Market Size By Type (RIT 4385, Schwarz), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Mumps Drug Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.4 billion by 2031, growing at a CAGR of 10.1% during the forecast period of 2023 to 2031. The rising incidence of mumps outbreaks, particularly in regions with suboptimal vaccination coverage, is driving the demand for effective antiviral and supportive drug therapies. Additionally, increasing investments in healthcare infrastructure, awareness initiatives, and the development of novel drug formulations are expected to bolster market growth over the forecast period.

Drivers:

1. Rising Mumps Incidence and Resurgence of Outbreaks: Despite global vaccination efforts, mumps outbreaks continue to occur, especially among adolescents and young adults in regions with waning immunity. This trend is fueling demand for effective mumps treatment drugs and combination therapies.

2. Increasing Government Health Expenditure: Growing health budgets in emerging economies and funding support for infectious disease control are enabling the procurement of mumps-related drug supplies and research initiatives.

3. Pipeline Drugs and Combination Therapies: The introduction of new antiviral combinations and pipeline drugs targeting mumps-specific symptoms presents a strong growth trajectory for the global market.

Restraints:

1. High Dependence on Vaccination Over Therapeutics: The widespread use of the MMR (measles, mumps, and rubella) vaccine continues to dominate mumps prevention efforts, which reduces the direct demand for mumps-specific therapeutics in many countries.

2. Limited Commercial Interest from Pharma Companies: Mumps is considered a preventable disease, limiting the incentive for large pharmaceutical companies to invest heavily in mumps-specific drug development.

Opportunity:

1. Unmet Needs in Developing Countries: Regions with limited vaccine coverage or compromised healthcare infrastructure present significant opportunities for therapeutic intervention, especially during outbreaks.

2. Advances in Antiviral Drug Research: The development of targeted antivirals that inhibit mumps virus replication offers potential for innovative treatments and expanded indications beyond supportive care.

3. Strategic Collaborations and R&D Funding: Public-private partnerships, along with research grants from international health organizations, are fostering innovation in mumps drug development.

Market by Drug Type Insights:

In 2023, supportive care drugs such as analgesics, antipyretics, and anti-inflammatory agents dominated the market. These remain essential for symptom management during mumps infection. However, the antiviral drug segment is projected to grow at the highest CAGR due to ongoing clinical trials and growing awareness about viral suppression strategies during outbreaks.

Market by End-use Insights:

The hospital pharmacies segment accounted for the largest market share in 2023, owing to the increasing hospitalization rates during mumps complications like orchitis and meningitis. Retail pharmacies are also gaining traction, particularly in urban and semi-urban areas, driven by growing self-medication practices and easy access to over-the-counter supportive drugs.

Market by Regional Insights:

North America led the market in 2023, driven by recurring outbreak clusters in university campuses and healthcare settings, alongside strong healthcare infrastructure. Asia-Pacific is expected to experience the fastest growth during the forecast period due to rising public health investments, expanding pharmaceutical manufacturing, and growing disease burden in densely populated countries like India and Indonesia.

Competitive Scenario:

Key players in the Global Mumps Drug Market include GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., and Abbott Laboratories. These companies are actively involved in drug repurposing strategies, vaccine adjacents, and research collaborations to expand their product pipelines.

Scope of Work – Global Mumps Drug Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.4 billion

CAGR (2023–2031) 10.1%

Market Segments By Drug Type (Antiviral Drugs, Supportive Care Drugs), By End-use (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region

Growth Drivers Resurgence of mumps outbreaks, increased healthcare spending, and R&D in antiviral drugs

Opportunities Drug innovation, unmet needs in developing regions, government and NGO collaborations

Key Market Developments:

2023: Roche initiated early-phase trials for a broad-spectrum antiviral that includes efficacy against mumps virus.

2024: GlaxoSmithKline announced the launch of an advanced mumps symptom relief drug in Asia-Pacific, targeting underserved markets.

2025: Pfizer and a Southeast Asian health agency entered a collaboration for mumps treatment access and awareness programs across rural populations.

FAQs:

1) What is the current market size of the Global Mumps Drug Market?

The Global Mumps Drug Market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Mumps Drug Market?

The resurgence of mumps outbreaks and the growing focus on antiviral drug development are key drivers of market growth.

3) Which is the largest region during the forecast period in the Global Mumps Drug Market?

North America is expected to remain the leading region throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Mumps Drug Market?

Supportive care drugs held the largest market share in 2023.

5) Who are the key market players in the Global Mumps Drug Market?

Key players include GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., and Novartis AG.